

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer

The AvaALL Randomized Clinical Trial

Cesare Gridelli, MD; Javier de Castro Carpeno, MD; Anne-Marie C. Dingemans, MD, PhD; Frank Griesinger, MD; Francesco Grossi, MD; Corey Langer, MD, FACP; Yuichiro Ohe, MD; Konstantinos Syrigos, MD, PhD, FCCP; Nick Thatcher, PhD, FRCP; Ashis Das-Gupta, MD, FRCS; Matt Truman, MSc; Margarita Donica, MSc; Vlatka Smoljanovic, MD; Jaafar Bennouna, MD

 [Supplemental content](#)

IMPORTANCE Bevacizumab treatment beyond progression has been investigated in breast and metastatic colorectal cancers. Avastin in All Lines Lung (AvaALL) is the first randomized phase 3 study of bevacizumab across multiple lines of treatment beyond progression in non-small cell lung cancer (NSCLC).

OBJECTIVE To assess the efficacy and safety of continuous bevacizumab treatment beyond first progression in NSCLC.

DESIGN, SETTING, AND PARTICIPANTS AvaALL was a randomized, open-label, phase 3b trial, conducted from 2011 to 2015 in 123 centers worldwide. Patients with nonsquamous NSCLC previously treated with first-line bevacizumab plus platinum-doublet chemotherapy and at least 2 cycles of bevacizumab maintenance were randomized (1:1) at first progression to receive bevacizumab plus standard of care (SOC) or SOC alone.

INTERVENTIONS Patients received bevacizumab (7.5 or 15 mg/kg intravenously every 21 days) and/or investigator's choice of SOC. For subsequent lines, patients treated with bevacizumab received SOC with or without bevacizumab; the SOC arm received SOC only.

MAIN OUTCOMES AND MEASURES The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival from first to second (PFS2) and third progression (PFS3), time to second (TTP2) and third progression (TTP3), and safety.

RESULTS Between June 2011 and January 2015, 485 patients (median age, 63.0 years [range, 26-84 years]; 293 [60.4%] male) were randomized. Median OS was not significantly longer with bevacizumab plus SOC vs SOC alone: 11.9 (90% CI, 10.2-13.7) vs 10.2 (90% CI, 8.6-11.9) months (hazard ratio [HR], 0.84; 90% CI, 0.71-1.00; $P = .104$). Median PFS2 was numerically longer with bevacizumab plus SOC vs SOC alone: 5.5 (90% CI, 4.2-5.7) vs 4.0 (90% CI, 3.4-4.3) months (HR, 0.83; 90% CI, 0.70-0.98; $P = .06$). Median PFS3 appeared longer with bevacizumab plus SOC vs SOC alone: 4.0 (90% CI, 2.9-4.5) vs 2.6 (90% CI, 2.3-2.9) months (HR, 0.63; 90% CI, 0.49-0.83), as did TTP2 and TTP3. Grade 3/4 adverse events were more frequent with bevacizumab plus SOC (186 [76.5%]) vs SOC alone (140 [60.3%]). No new safety signals were observed.

CONCLUSIONS AND RELEVANCE The primary end point was not met; however, OS was underpowered according to initial statistical assumptions. Continued therapy beyond first progression led to improved PFS3 (but not PFS2), TTP2, and TTP3. Although a result with $P = .06$ for PFS2 would conventionally be considered significant at a specified 2-sided α of .10, in the absence of adjustments for multiplicity, this result could be a chance finding. No new safety signals were identified with bevacizumab treatment beyond progression.

TRIAL REGISTRATION clinicaltrialsregister.eu Identifier: [2010-022645-14](#); ClinicalTrials.gov identifier: [NCT01351415](#)

JAMA Oncol. 2018;4(12):e183486. doi:[10.1001/jamaoncol.2018.3486](#)
Published online August 30, 2018. Corrected on December 13, 2018.

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Cesare Gridelli, MD, Division of Medical Oncology, S.G. Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy (cgridelli@libero.it).

Retrospective analyses suggested a survival benefit of bevacizumab continuation after induction therapy in advanced non-small cell lung cancer (NSCLC).^{1,2} The randomized, phase 2 West Japan Oncology Group (WJOG) 5910L trial in advanced nonsquamous NSCLC demonstrated a modest progression-free survival (PFS) benefit and a nonsignificant finding of improved overall survival (OS) with bevacizumab beyond progression.³ The Avastin Registry: Investigation of Effectiveness and Safety (ARIES) observational analysis suggested that cumulative bevacizumab use after progression prolonged OS in patients with metastatic colorectal cancer.⁴ These data were confirmed in a phase 3, open-label trial (ML18147).⁵ The phase 3 TANIA breast cancer study also showed improved PFS with continued bevacizumab plus chemotherapy vs chemotherapy alone.⁶

The open-label, randomized phase 3b Avastin in All Lines Lung (AvaALL) study assessed the efficacy and safety of bevacizumab beyond first progression in advanced NSCLC following bevacizumab maintenance therapy.

Methods

Study Design

AvaALL investigated standard-of-care (SOC) chemotherapy with or without bevacizumab beyond first progression in patients with advanced, nonsquamous NSCLC. The study was undertaken in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice Guidelines; written informed consent was obtained from all patients. The study was approved by local institutional review boards at each study site (protocol available in [Supplement 1](#)).

At first progression, patients were randomized 1:1 to receive second-line investigator's choice of SOC with or without bevacizumab (7.5 or 15 mg/kg every 21 days). At second and third progression, patients receiving bevacizumab received SOC with or without bevacizumab; the SOC arm received SOC only. Beyond third progression, bevacizumab was continued at the investigator's discretion, in the absence of unacceptable toxic effects or consent withdrawal. The same dose of bevacizumab (investigator's choice) was continued throughout all lines of treatment.

Objectives

The primary objective was OS beyond first progression of continuous bevacizumab therapy vs SOC. Secondary objectives included PFS from randomization at first progression to second (PFS2) and third progression (PFS3), time to progression (TTP) from randomization at first progression to second (TTP2) and third progression (TTP3) (eFigure 1 in [Supplement 2](#)), and safety.

Patients

Inclusion criteria were as follows: nonsquamous NSCLC progressing following first-line bevacizumab (4-6 cycles) plus platinum-doublet chemotherapy, and at least 2 cycles of bevacizumab maintenance monotherapy prior to first progression; more than 2 consecutive cycles of bevacizumab between end of first-line and first day of second-line treatment; at least 1


Key Points

Question Is there a benefit of continuing bevacizumab treatment beyond disease progression in patients with non-small cell lung cancer (NSCLC)?

Findings In this randomized clinical trial of 485 patients with advanced, nonsquamous NSCLC, the primary end point was not met; median overall survival was not significantly different between groups. No new safety signals were identified with bevacizumab treatment beyond disease progression.

Meaning Continued bevacizumab treatment beyond disease progression did not demonstrate survival benefit.

Figure 1. Patient Disposition



ITT indicates intent to treat; SOC, standard of care.


measurable lesion (Response Evaluation Criteria In Solid Tumors, version 1.1); and Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2. Patients with asymptomatic treated brain metastases were eligible if treatment was completed at least 28 days before randomization.

Exclusion criteria were as follows: mixed non-small cell and small cell tumors or mixed adenosquamous carcinomas with predominant squamous component; epidermal growth factor receptor mutation-positive disease; grade at least 2 hemoptysis 3 months or less before randomization; tumor invading a major blood vessel on imaging; radiotherapy 28 days or less before randomization.

Statistical Analyses

Approximately 416 OS events were required to achieve 80% power for the stratified log-rank test at a 1-sided 5% signifi-

Figure 2. Kaplan-Meier Plot of Overall Survival (OS) in the Intent-to-Treat Population



cance level (overall 10% 2-sided, $P < .10$) for the final OS analysis (500 randomized patients); this would detect a difference between median OS of 10 months (SOC) vs 12.8 months (bevacizumab) (corresponding hazard ratio [HR], 0.78). Allowing for a 2% dropout rate, 250 patients per arm were planned.

Overall survival was defined as time from randomization at first progression to date of death. Progression-free survival was defined as time from randomization until progression or death, and TTP as time from randomization until objective tumor progression; neither were adjusted for multiple testing. Progression-free survival, TTP, and OS were calculated using Kaplan-Meier methodology and between-treatment differences tested by stratified log-rank test (10% significance level). Hazard ratios and 90% confidence intervals were estimated on a stratified Cox model. Adverse events (AEs) were graded using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

Results

Patients

Between June 2011 and January 2015, 485 patients were randomized (bevacizumab, $n = 245$; SOC, $n = 240$), of whom 475 received treatment (bevacizumab, $n = 243$; SOC, $n = 232$) (Figure 1). Baseline characteristics were balanced (eTable 1 in Supplement 2).

Efficacy

The final cutoff date was June 24, 2016. The primary analysis was conducted 60 months after first patient enrollment (prespecified in the protocol); the database closed with 387 OS events. Median OS (Figure 2) was numerically longer with bevacizumab plus SOC vs SOC but was not statistically significant (11.9 [90% CI, 10.2-13.7] vs 10.2 [90% CI, 8.6-11.9] months; stratified HR, 0.84; 90% CI, 0.71-1.00; $P = .104$). Subgroup

Table. Adverse Events of Special Interest (AESIs) With Preferred Term Reported for at Least 1% of Patients Overall (Safety Population)

System Organ Class and Preferred Term	No. (%) Bevacizumab Plus SOC (n = 243)	SOC Alone (n = 232)
Any AESI	118 (48.6)	63 (27.2)
Arterial and venous thromboembolic events	26 (10.7)	21 (9.1)
Vascular disorders	12 (4.9)	14 (6.0)
Venous thrombosis	3 (1.2)	3 (1.3)
Deep vein thrombosis	3 (1.2)	2 (0.9)
Respiratory, thoracic, and mediastinal disorders	12 (4.9)	9 (3.9)
Pulmonary embolism	11 (4.5)	9 (3.9)
Hypertension	55 (22.6)	28 (12.1)
Vascular disorders	54 (22.2)	28 (12.1)
Hypertension	53 (21.8)	25 (10.8)
Proteinuria	51 (21.0)	24 (10.3)
Renal and urinary disorders	51 (21.0)	24 (10.3)
Proteinuria	51 (21.0)	23 (9.9)

Abbreviation: SOC, standard of care.

analyses showed similar results (eFigure 2 in Supplement 2), except in never smokers or patients older than 75 years.

Median OS did not differ according to bevacizumab dose of 7.5 mg/kg plus SOC (11.4 vs 10.2 months SOC alone; stratified HR, 0.86; 90% CI, 0.69-1.07) or 15 mg/kg plus SOC (12.6 vs 10.2 months SOC alone; stratified HR, 0.84; 90% CI, 0.68-1.04). Median PFS2 was numerically longer with bevacizumab plus SOC vs SOC alone (5.5 [90% CI, 4.2-5.7] vs 4.0 [90% CI, 3.4-4.3] months; stratified HR, 0.83; 90% CI, 0.70-0.98; $P = .06$) (eFigure 3A in Supplement 2). Subgroup analysis showed similar findings (eFigure 3B in Supplement 2), except patients with ECOG PS 2 or never smokers. Median PFS3 was longer with bevacizumab vs SOC (4.0 [90% CI, 2.9-4.5] vs 2.6

[90% CI, 2.3-2.9] months; HR, 0.63; 90% CI, 0.49-0.83) (eFigure 4 in Supplement 2), as were TTP2 and TTP3 (eFigure 5 and eFigure 6 in Supplement 2).

Safety

Treatment exposure is reported in eTable 2 in Supplement 2. No new safety signals were identified. Adverse events of special interest (Table) and grade 3/4 AEs (eTable 3 in Supplement 2) were more frequent with bevacizumab plus SOC vs SOC alone (118 [48.6%] vs 63 [27.2%] and 186 [76.5%] vs 140 [60.3%], respectively). Sixteen bevacizumab-treated patients (6.6%) and 12 SOC-treated patients (5.2%) experienced grade 5 treatment-related AEs (eTable 4 and eTable 5 in Supplement 2).

Discussion

AvaALL is the first randomized phase 3 study to analyze bevacizumab across multiple lines of treatment beyond progression in NSCLC. The protocol-specified OS end point was not met. However, there was a nonsignificant finding of improved median OS in the bevacizumab vs the SOC arm. As a result of recruitment challenges, the analysis was performed after 60 months, at 387 OS events, and was therefore underpowered. Time to PFS2 was numerically longer with bevacizumab plus SOC vs SOC alone, although no formal testing was performed. These results align with WJOG 5910L, which was also underpowered as a result of enrollment issues.³ Both TTP2 and TTP3 were significantly longer

with bevacizumab plus SOC vs SOC alone. However, no multiplicity adjustment was performed; therefore, these findings should be interpreted with caution.

Survival data in most subgroups were similar to the overall population, except for never smokers, patients older than 75 years, or those with ECOG PS 2. Similar results were reported for never smokers in WJOG 5910L.³ Never smokers have distinct molecular tumor profiles vs smokers,^{7,8} which may affect treatment response. Furthermore, patients older than 75 years and those with a higher ECOG PS may be more susceptible to AEs. Low patient numbers in these subgroups prevent definitive conclusions from being drawn. No unexpected AEs were reported, with more grade at least 3 AEs in the bevacizumab vs the SOC arm, consistent with previous studies.^{3,5}

Since AvaALL began accrual, major changes have occurred to second-line SOC. Checkpoint inhibitors have been approved for locally advanced or metastatic NSCLC after disease progression on platinum-doublet chemotherapy.⁹ These have displaced pemetrexed and docetaxel from second line, while erlotinib is no longer approved in this setting.^{10,11} Recent trials have thus rendered the control arm of AvaALL outmoded.

Conclusions

A substantial benefit of bevacizumab therapy beyond progression in patients with NSCLC was not shown, but some improvements in efficacy were observed. No new safety signals were identified.

ARTICLE INFORMATION

Accepted for Publication: June 7, 2018.

Correction: This article was corrected on December 13, 2018, to fix errors in Figure 2.

Published Online: August 30, 2018.

doi:10.1001/jamaoncol.2018.3486

Author Affiliations: Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy (Gridelli); Division of Medical Oncology, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain (de Castro Carpeno); Department of Pulmonology, Maastricht University Medical Center, Maastricht, the Netherlands (Dingemans); Department of Hematology and Oncology, University Department of Internal Medicine-Oncology, Pius-Hospital, University of Oldenburg, Oldenburg, Germany (Griesinger); Lung Cancer Unit, Ospedale Policlinico San Martino, Genova, Italy (Grossi); Thoracic Oncology Unit, Abramson Cancer Center, University of Pennsylvania, Philadelphia (Langer); Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan (Ohe); Department of Medicine, National and Kapodistrian University, Athens, Greece (Syrigos); Christie Hospital NHS Trust, Manchester, United Kingdom (Thatcher); F. Hoffmann-La Roche Ltd, Basel, Switzerland (Das-Gupta, Donica, Smoljanovic); Roche Products Pty Ltd, Sydney, New South Wales, Australia (Truman); Now with OzBiostat Pty Ltd, Manly, New South Wales, Australia (Truman); Institut de Cancérologie de l'Ouest, Nantes, France (Bennouna).

Author Contributions: Ms Donica had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Gridelli, de Castro Carpeno, Dingemans, Griesinger, Langer, Thatcher, Bennouna. **Acquisition, analysis, or interpretation of data:** Gridelli, de Castro Carpeno, Dingemans, Griesinger, Grossi, Langer, Ohe, Syrigos, Das-Gupta, Truman, Donica, Smoljanovic, Bennouna.

Drafting of the manuscript: Gridelli, de Castro Carpeno, Smoljanovic.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Das-Gupta, Truman, Donica.

Obtained funding: Ohe, Das-Gupta.

Administrative, technical, or material support: Dingemans, Langer, Syrigos, Thatcher, Das-Gupta, Smoljanovic.

Study supervision: de Castro Carpeno, Dingemans, Griesinger, Syrigos, Das-Gupta, Smoljanovic, Bennouna.

Conflict of Interest Disclosures: Dr Gridelli has acted in a consulting or advisory role for Roche, Merck Sharp & Dohme, and Bristol-Myers Squibb, and participated in speaker bureaus for Merck Sharp & Dohme, Bristol-Myers Squibb, and Pfizer. Dr de Castro Carpeno has acted in a consulting or advisory role for Pfizer, AstraZeneca, Roche, Merck Sharp & Dohme, Bristol-Myers Squibb, and Boehringer Ingelheim, and has received travel, accommodation, or expenses from Roche and Bristol-Myers Squibb. Dr Dingemans has acted in a

consulting or advisory role for Roche, Bristol-Myers Squibb, Merck Sharp & Dohme, Boehringer Ingelheim, and AstraZeneca. Dr Griesinger has received honoraria from Roche, AstraZeneca, Boehringer Ingelheim, Lilly, Novartis, Pfizer, Merck Sharp & Dohme, Bristol-Myers Squibb, Celgene, and Takeda, and has received research funding from Roche, AstraZeneca, Boehringer Ingelheim, Lilly, Novartis, Pfizer, Merck Sharp & Dohme, Bristol-Myers Squibb, and Celgene. Dr Grossi has acted in a consulting or advisory role for Roche. Dr Langer has received honoraria from Bristol-Myers Squibb, Genentech/Roche, and Eli Lilly/ImClone; has acted in a consulting or advisory role for Genentech/Roche, Eli Lilly/ImClone, Merck, Abbott Biotherapeutics, Bayer/Onyx, Clariant, Clovis Oncology, Celgene, Cancer Support Community, Bristol-Myers Squibb, ARIAD, and AstraZeneca; and has received research funding from Merck, Advantagene, Clovis Oncology, Celgene, Inovio Pharmaceuticals, ARIAD, GlaxoSmithKline, Genentech/Roche, and Stemcentrx. Dr Ohe has an immediate family member who holds stock or other ownership interest in Ono Pharmaceuticals; has received honoraria from AstraZeneca, Chugai Pharma, Lilly Japan, Ono Pharmaceutical, Bristol-Myers Squibb Japan, Daiichi Sankyo, Nippon Kayaku, Boehringer Ingelheim, Bayer, Pfizer, Merck Sharp & Dohme, Taiho Pharmaceutical, Novartis, Kyorin, and Kyowa Hakko Kirin; has acted in a consulting or advisory role for AstraZeneca, Chugai Pharma, Lilly Japan, Ono Pharmaceutical, and Novartis; has received research funding from

AstraZeneca, Chugai Pharma, Lilly Japan, Ono Pharmaceutical, Bristol-Myers Squibb Japan, Kyorin, Dainippon Sumitomo Pharma, Pfizer, Taiho Pharmaceutical, and Novartis; and has given expert testimony for AstraZeneca and Ono Pharmaceutical. Dr Thatcher has received honoraria from Roche, Lilly, Celgene, Boehringer Ingelheim, Stemcentrix, Amgen, and Otsuka; has acted in a consulting or advisory role for Roche, Lilly, Celgene, Boehringer Ingelheim, Stemcentrix, Amgen, and Otsuka; has participated in speaker bureaus for Roche, Lilly, Celgene, Boehringer Ingelheim, Stemcentrix, Amgen, and Otsuka; and has provided expert testimony on behalf of Lilly. Dr Das-Gupta is an employee of F. Hoffmann-La Roche Ltd, holds stock or other ownership interest from F. Hoffmann-La Roche Ltd, and has received travel, accommodation, or expenses from F. Hoffmann-La Roche Ltd. Mr Truman holds stock or other ownership interest in Roche Products Ltd; has acted in a consulting or advisory role for Roche Products Ltd and Aurinia Pharmaceuticals; and has received travel, accommodation, or expenses from Roche Products Ltd and Aurinia Pharmaceuticals. Ms Donica is an employee of F. Hoffmann-La Roche Ltd. Dr Smoljanovic is an employee of F. Hoffmann-La Roche Ltd; holds stock or other ownership interest in F. Hoffmann-La Roche Ltd; and has received travel, accommodation, or expenses from F. Hoffmann-La Roche Ltd. Dr Bennouna has received honoraria from Boehringer Ingelheim, Roche, AstraZeneca, and Bristol-Myers Squibb; and has acted in a consulting or advisory role for Boehringer Ingelheim, Roche, Bristol-Myers Squibb, and AstraZeneca. No other disclosures are reported.

Funding/Support: This work was funded by F. Hoffmann-La Roche Ltd.

Role of the Funder/Sponsor: F. Hoffmann-La Roche Ltd participated in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.

Meeting Presentation: This work was presented as an oral presentation at the American Society of Clinical Oncology annual meeting; June 6, 2017; Chicago, Illinois (abstract 9004).

Additional Contributions: Third-party medical writing assistance was provided by Rachel Hubbard, MSc, of Gardiner-Caldwell Communications, and was funded by F. Hoffmann-La Roche Ltd.

Data Sharing: Qualified researchers may request access to individual patient-level data through the clinical study data request platform (<https://www.clinicalstudydatarequest.com>). Further details on Roche's criteria for eligible studies are available at <https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx>. For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see https://www.roche.com/research_and_development/who_we_are/how_we_work/clinical_trials/our_commitment_to_data_sharing.htm.

REFERENCES

1. Kosty MP, Wozniak AJ, Jahanzeb M, et al. Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study. *Target Oncol*. 2015;10(4):509-516. doi:10.1007/s11523-014-0355-4
2. Nadler E, Yu E, Ravelo A, Sing A, Forsyth M, Gruschus S. Bevacizumab treatment to progression after chemotherapy: outcomes from a US community practice network. *Oncologist*. 2011;16(4):486-496. doi:10.1634/theoncologist.2010-0287
3. Takeda M, Yamanaka T, Seto T, et al. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group S910L): an open-label, randomized, phase 2 trial. *Cancer*. 2016;122(7):1050-1059. doi:10.1002/cnrc.29893
4. Grothey A, Flick ED, Cohn AL, et al. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. *Pharmacoeconom Drug Saf*. 2014;23(7):726-734. doi:10.1002/pds.3633
5. Bennouna J, Sastre J, Arnold D, et al; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. *Lancet Oncol*. 2013;14(1):29-37. doi:10.1016/S1470-2045(12)70477-1
6. von Minckwitz G, Puglisi F, Cortes J, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. *Lancet Oncol*. 2014;15(11):1269-1278. doi:10.1016/S1470-2045(14)70439-5
7. Gibelin C, Couraud S. Somatic alterations in lung cancer: do environmental factors matter? *Lung Cancer*. 2016;100:45-52. doi:10.1016/j.lungcan.2016.07.015
8. Subramanian J, Govindan R. Molecular profile of lung cancer in never smokers. *EJC Suppl*. 2013;11(2):248-253. doi:10.1016/j.ejcsup.2013.07.004
9. La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB. Immune checkpoint inhibitors: new insights and current place in cancer therapy. *Pharmacotherapy*. 2015;35(10):963-976. doi:10.1002/phar.1643
10. Tarceva (erlotinib) [package insert]. Melville, NY: OSI Pharmaceuticals; 2004. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021743lbl.pdf. Accessed January 1, 2018.
11. Erlotinib summary of product characteristics. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000618/WC500033994.pdf. Accessed January 1, 2018.